Company intelligence / Profile preview

Re-creation Biopharmaceutical

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

Re-creation Biopharmaceutical is a clinical-stage biotechnology company based in Beijing, China, focused on the development of innovative biologics for oncology and hematology. The company's lead candidate, CPAT (Circularly Permuted TRAIL), is a recombinant protein designed to induce apoptosis in cancer cells by targeting death receptors. Re-creation is currently advancing its pipeline through late-stage clinical trials, with a primary focus on treating multiple myeloma and various solid tumors. Their research leverages protein engineering to improve the stability and efficacy of apoptosis-inducing therapies.

Therapeutic areas: Oncology
Modalities: Recombinant proteinBiologicFusion proteinMonoclonal antibody
Industry: Biotech

Beyond the preview

Go deeper on Re-creation Biopharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Re-creation Biopharmaceutical.

Explore the full profile